COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report
Authors:
- Vasiliki SyrmouVSVasiliki Syrmou
- Christos LiaskosCLChristos Liaskos
- Niki NtavariNNNiki Ntavari
- Konstantinos MitsimponasKMKonstantinos Mitsimponas
- Theodora SimopoulouTSTheodora Simopoulou
- Ioannis AlexiouIAIoannis Alexiou
- Marianna VlychouMVMarianna Vlychou
- Christina G. KatsiariCKChristina G. Katsiari
- Dimitrios P. BogdanosDimitrios P. Bogdanos
Open Access
- 16 March 2023
- journal article
- review article
- Published by Springer Nature in Immunologic Research
- Vol. 71 (4) , 537-546
Abstract
Several cases of vaccine-associated manifestations have been published including cases of inflammatory myositis. Herein, we comprehensively review the literature on the occasion of case of a woman with inflammatory myositis following COVID-19 vaccination. A 67-year-old woman presented with left arm edema, rash, and weakness after the 2nd dose of the BTN162b2 vaccine. Raised muscle enzymes and inflammatory markers with muscle edema on MRI and myositis findings on the electromyogram established the diagnosis. She was successfully treated with methylprednisolone pulses, intravenous immunoglobulin, methotrexate, and hydroxychloroquine. Cases of inflammatory myositis, dermatomyositis, or interstitial lung disease with myositis-specific autoantibodies or myositis-associated autoantibodies within 12 weeks from SARS-CoV-2 vaccination were included. Cases with malignancy, prior or subsequent COVID-19 infection, preexisting myositis/interstitial lung disease (ILD)/dermatomyositis (DM), or other connective tissue diseases were excluded. From our search, 49 cases were identified (mean age: 56.55 + 17.17 years), 59% were women, while 12 patients received the ChAdOx1 vaccine, 27 the BNT162b2, 8 the mRNA-1273, 1 the DB15806, and 1 the Ad26.COV2.S (overall, 70% received mRNA vaccines). Muscle involvement was the most common manifestation (79.5%), followed by skin involvement (53%) and ILD (34.6%), which were more common in the m-RNA vaccinees. Muscle biopsy, MRI findings, and autoantibody profile varied significantly, while successful immunosuppressive treatment was applied in most cases. Inflammatory myositis after COVID-19 vaccination has been well documented worldwide. Current evidence in support of a pathogenic link is challenging due to significant variation in clinical manifestations, radiological, histopathological, and immunological features.Keywords
Funding Information
- University of Thessaly Central Library
This publication has 37 references indexed in Scilit:
- Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case–control studyAnnals of the Rheumatic Diseases, 2017
- TLR4-HMGB1 signaling pathway affects the inflammatory reaction of autoimmune myositis by regulating MHC-IInternational Immunopharmacology, 2016
- Nucleic acid‐sensing TLRs and autoimmunity: novel insights from structural and cell biologyImmunological Reviews, 2015
- Nucleic acid vaccination strategies against infectious diseasesExpert Opinion on Drug Delivery, 2015
- Pattern Recognition and Signaling Mechanisms of RIG-I and MDA5Frontiers in Immunology, 2014
- TLR4 as receptor for HMGB1 induced muscle dysfunction in myositisAnnals of the Rheumatic Diseases, 2013
- HBV vaccine and dermatomyositis: is there an association?Rheumatology International, 2007
- Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groupsArthritis & Rheumatism, 2005
- Polymyositis: rare complication of hepatitis B vaccination. An unusual cause of toxic shock syndrome.2004
- Dermatomyositis Associated With BCG VaccinationScandinavian Journal of Rheumatology, 1979